1.	Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: Not specifiec Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001C2X01B, NCT01789281
2.	A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AAA-III-01, 2011-005049-11, NCT01578239
3.	Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 to 80 Sponsor: Other Protocol IDs: LOTUS, 2011-006097-76, NCT01755182
4.	Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 4P-11-3, NCI-2011-03266, NCT01469338